Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A) in patients with advanced solid cancer

スポンサーリンク

概要

• 論文の詳細を見る
• 2001-10-01

著者

• Levitt N.

  Churchill Hospital

• Talbot D.

  Churchill Hospital

• Steward W.

  Leicester Royal Infirmary

• ESKENS F.

  Rotterdam Cancer Institute

• PROPPER D.

  Churchill Hospital

• DENIS L.

  Rotterdam Cancer Institute

• OWEN S.

  Novartis Pharma

• CHOI L.

  Novartis Pharma

• FOEKENS J.

  Rotterdam Cancer Institute

• WILNER S.

  Churchill Hospital

• WOOD J.

  Novartis Pharma

• NAKAJIMA M

  Novartis Pharma

• HARRIS A.

  Churchill Hospital

• VERWEIJ J.

  Rotterdam Cancer Institute

• O'byrne K.

  Leicester Royal Infirmary

関連論文

• Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A) in patients with advanced solid cancer

スポンサーリンク